yahoo! | innovative alzheimer's treatment from china concludes phase 3 clinical trials-pg电子官方

pg电子官方-pg电子游戏平台
about us
about us
green valley is an innovative chinese pharmaceutical company that pioneers carbohydrate drugs development and manufacturing in the world.
about green valley
our business
mission & vision
our culture
code of business ethics
gv-971
gv-971
here you can get access to more information of gv-971.
products
news reports
research highlights
milestones
scientific research information
scientific research information
originality is the soul of our innovation in scientific research. we are devoted to developing drugs and healthcare solutions that patients are in the greatest need of.
life sciences innovation
research parteners
news
news
here you can get access to the latest news reports of green valley.
press releases
news reports
social responsibility
careers
apart from the competitive compensation & benefits programs, we have developed a detailed benefits and perks scheme. we respect, appreciate and reward the contributions of every employee for their hard work and dedication.
salary and benefits
contact us
contact us
media contacts
pg电子官方-pg电子游戏平台
news reports
news reports
press releases
news reports
press releases
news reports
yahoo! | innovative alzheimer's treatment from china concludes phase 3 clinical trials
date：2018-07-27

1533204521839492.png


innovative alzheimer's treatment from china concludes phase 3 clinical trials green valley plans to submit the application for treatment to the china national drug administration this year


shanghai, july 19, 2018 /prnewswire/ --  shanghai green valley pharmaceutical co., ltd. (green valley) today announced that its phase 3 study of sodium oligomannurarate (gv-971) capsules on mild-to-moderate alzheimer's disease met its primary endpoint.


this randomized, double-blinded and placebo-controlled clinical trial in china aimed to evaluate safety and efficacy of gv-971, a multi-targeting oligosaccharide drug, on study participants with mild-to-moderate alzheimer's disease (mmse score ranged from 11 to 26). on the treatment arm, subjects took 450mg gv-971 orally twice each day for 36 weeks. the primary endpoint showed the improved change of the alzheimer's disease assessment scale-cognitive (adas-cog) score after the 36 week gv-971 treatment compared to the placebo control. data showed that gv-971 significantly improved the cognition impairment. regarding the rate of adverse events, gv-971 showed a similar profile to that of the placebo control, no amyloid-related imaging abnormalities (aria) were observed.


alzheimer's disease is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive function. according to alzheimer's disease international, there are approximately 48 million patients world-wide with alzheimer's disease, and this number is expected to reach 130 million by 2050 due to a rapid growth of the aging population.


green valley plans to submit the marketing authorization application of gv-971 for treatment of mild-to-moderate alzheimer's disease to the china national drug administration later this year.


shareto：
previous page：
cctv-news | gv-971, a novel ad drug treatment developed by chinese research team, grabs much of attention at ctad
next page：
none
网站地图
contact us
green valley headquarters

address: 421 newton road, zhangjiang hi-tech park, pudong new area, shanghai, china

phone: 86 021-50540520

quick links
company overview
contact us
focus areas & products
report a possible side effect
news
green valley

*this website is only intended for people to seek information on green valley's business instead of medical advice or medical consultation. medical advice and consultation must be provided by doctors or other qualified healthcare professionals. the information contained in this website shall not be used for the diagnosis of diseases.  

 "));
pg电子游戏平台 copyright noticelegal noticeterms of use
网站地图